Clinical Trial Update: Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating extended-release naltrexone to prevent opioid relapse after release from jail has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Vivitrol (naltrexone extended-release injectable)

Snippet

Sponsor: NYU Langone Health | Conditions: Opiate Dependence | Phase 3 | Status: COMPLETED | Results posted: 2016-04-07